5/24/2022 | BK | Halozyme closes $600 million revolving, term loans for Antares merger
|
6/27/2019 | PV | Antares Pharma lifts term loan with Hercules Capital to $50 million
|
6/13/2018 | EMHYPFPV | Market Commentary: High-grade volume quiet; Bayer, Digital Realty, Antares hold investor calls; AT&T flat
|
6/13/2018 | IG | Market Commentary: High-grade volume quiet; Bayer, Digital Realty, Antares hold investor calls; AT&T flat
|
5/6/2015 | PP | Antares Pharma prices its $40 million public stock offering at $2.00
|
5/5/2015 | PP | Antares Pharma reports plans to price public offering of common stock
|
10/3/2012 | PP | Antares Pharma prices $50 million public sale of common stock at $4.00
|
10/2/2012 | PP | Antares Pharma intends to price public offering of its common shares
|
5/18/2011 | PP | Antares Pharma greenshoe exercised, company sells $23 million of stock
|
5/13/2011 | PP | Antares Pharma prices $20 million public offering of common stock
|
7/2/2010 | CVHYPF | Antares Pharma files $100 million shelf for preferreds, debt, stock
|
9/18/2009 | PP | New Issue: Antares to sell $3 million of units in registered direct offering
|
7/24/2009 | PP | New Issue: Antares Pharma to raise $8.5 million in direct offering of equity units
|
7/24/2009 | PP | Market Commentary: CytRx to sell equity; Prolor retires credit line with placement funds; Cyclacel plans offering
|
4/17/2009 | CV | Antares Pharma files $20 million shelf that includes convertibles
|
7/10/2007 | PP | New Issue: Antares raises another $1 million, lifts stock sale to $16.04 million
|
7/2/2007 | PP | Market Commentary: Linn Energy secures $1.5 billion from units; American Home pockets $125 million
|
6/29/2007 | PP | New Issue: Antares Pharma to close $15.04 million stock offering
|
6/29/2007 | PP | Market Commentary: Primus seals $20.58 million direct placement; Ener1 raises $15 million
|
3/5/2007 | PP | Market Commentary: Austindo plans $20 million convertible note offering; Veridigm prices $4.5 million of stock
|
3/2/2007 | PP | New Issue: Antares Pharma receives $10 million credit agreement with warrants
|
3/2/2007 | PP | Market Commentary: Iomai pockets $31.8 million from unit offering; Antares raises $10 million from loan
|
9/28/2006 | BT | Antares to start phase 3 Anturol trial, plans to file NDA soon
|
8/14/2006 | BT | Antares second-quarter revenue rises, commercial progress continues
|
8/9/2006 | BT | Antares files 510(k) for needle-free hormone growth injection
|
7/18/2006 | BT | Antares, Teva sign license agreement for disposable injection device
|
6/26/2006 | BT | Antares meets with FDA following phase 2 trial of Anturol for overactive bladder
|
5/30/2006 | BT | Antares Pharma, Eli Lilly file joint patent application for needle-free injection device
|
4/24/2006 | BT | Antares says TecTix enhances drug absorption, reduces skin irritation
|
4/21/2006 | BT | Antares licensee BioSante submits NDA for transdermal estrogen product
|
3/21/2006 | BT | Antares Pharma reports fourth-quarter revenues up 3%, 2005 revenues down 19%
|
3/16/2006 | BT | Antares upgraded to strong buy by Dawson
|
3/1/2006 | PP | Market Commentary: Akorn secures $19.4 million from private placement; Procera closes $6 million stock deal
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/28/2006 | PP | Market Commentary: Advanced Life Sciences prepares to close $36 million PIPE; Antares to settle $10.9 million offering
|
2/28/2006 | BTPP | New Issue: Antares Pharma negotiates $10.96 million private placement of shares
|
2/22/2006 | BT | Antares phase 2 study shows Anturol for overactive bladder to be 'well-tolerated'
|
1/10/2006 | BT | Antares submits application to Amex to regain listing compliance
|
12/13/2005 | BT | Phase 2 studies of Antares' Anturol gel for overactive bladder nearing completion; phase 3 studies begin early 2006
|
11/29/2005 | BT | Antares signs deal with Teva unit for injection devices; unit buys 400,000 shares of Antares common stock
|
10/26/2005 | BT | Government officials express interest in Antares injectors to combat bioterrorism
|
7/11/2005 | BTPP | Antares Pharma exchanges 1.2 million shares for all outstanding 1,500 convertible preferreds
|